靶向DOT1L与EZH2协同打破弥漫性大B细胞淋巴瘤的生发中心身份
研究探讨表观遗传调控因子DOT1L和EZH2在生发中心B细胞样弥漫性大B细胞淋巴瘤(GCB-DLBCL)中的作用。GCB-DLBCL协同依赖DOT1L和EZH2活性,联合抑制两者导致多梳抑制复合物2靶基因去抑制增强、BCL6靶基因上调及MYC靶基因抑制,引发「细胞身份危机」,使细胞失去增殖性生发中心身份并部分发生浆细胞分化。体内联合用药抑制人GCB-DLBCL异种移植瘤生长。
要点
- GCB-DLBCL协同依赖DOT1L和EZH2的表观遗传活性。
- 联合抑制DOT1L和EZH2引发细胞身份危机并部分诱导浆细胞分化。
- 体内联合用药抑制人GCB-DLBCL异种移植瘤生长。
核心结论
- GCB-DLBCL的恶性行为强烈依赖DOT1L和EZH2,联合靶向这两种表观遗传写入酶可能为GCB-DLBCL提供基于分化的替代治疗模式。
研究设计与样本
- 研究探讨DOT1L和EZH2在GCB-DLBCL中的作用,并在体内人GCB-DLBCL异种移植瘤模型中验证联合用药效果。
主要发现
- GCB-DLBCL协同依赖DOT1L和EZH2的联合活性。
- 与EZH2单药处理相比,联合抑制两种酶增强多梳抑制复合物2靶基因的去抑制,同时上调BCL6靶基因并抑制MYC靶基因。
- 上述改变导致「细胞身份危机」,GCB-DLBCL失去增殖性生发中心身份并部分发生浆细胞分化,该状态与不良生存相关。
- 体内联合用药抑制人GCB-DLBCL异种移植瘤的生长。
临床怎么用
- 作者认为联合靶向DOT1L和EZH2可能为GCB-DLBCL提供基于分化的替代治疗模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Differentiation of antigen-activated B cells into proproliferative germinal center (GC) B cells depends on the activity of the transcription factors myelocytoma (MYC) and B-cell lymphoma 6 (BCL6), and the epigenetic writers disruptor of telomeric silencing 1-like (DOT1L) and enhancer of zeste homolog 2 (EZH2). GCB-like diffuse large B-cell lymphomas (GCB-DLBCLs) arise from GCB cells and closely resemble their cell of origin. Given the dependency of GCB cells on DOT1L and EZH2, we investigated the role of these epigenetic regulators in GCB-DLBCLs and observed that GCB-DLBCLs synergistically depend on the combined activity of DOT1L and EZH2. Mechanistically, inhibiting both enzymes led to enhanced derepression of polycomb repressive complex 2 target genes compared with EZH2 single treatment, along with the upregulation of BCL6 target genes and suppression of MYC target genes. The sum of all these alterations results in a "cell identity crisis," wherein GCB-DLBCLs lose their proproliferative GC identity and partially undergo plasma cell differentiation, a state associated with poor survival. In support of this model, combined epidrugging of DOT1L and EZH2 prohibited the outgrowth of human GCB-DLBCL xenografts in vivo. We conclude that the malignant behavior of GCB-DLBCLs strongly depends on DOT1L and EZH2 and that combined targeting of both epigenetic writers may provide an alternative differentiation-based treatment modality for GCB-DLBCL.
引用
- Göbel C, Niccolai R, de Groot MHP, et al. Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma. Blood. 2025. PMID: 39792929. doi:10.1182/blood.2024025500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。